Articles tagged with Cancer Medication
Scientists at Washington University School of Medicine identified over 850 DNA mutations linked to cancer that may be responsive to existing drugs. The study provides a list of mutations and associated drugs that could benefit patients, expanding the number of cancer treatments available.
Researchers have discovered a new way to slow the growth of aggressive triple negative breast cancer by targeting hypoxia, or low oxygen levels. The study found that drug JQ1 can alter how cancer cells respond to hypoxia, slowing tumour growth and limiting blood vessel production.
Researchers at the University of Cincinnati found that a pre-procedure medication regimen can significantly reduce hospital stays and readmission rates for liver cancer patients undergoing DEB TACE treatment. The study involved 113 procedures in 71 patients, with only 5% requiring hospital admission due to post-procedural syndrome.
A new study reverses resistance to antiangiogenic drugs by adding an antidiabetic agent, inhibiting tumor growth up to 92%. Researchers found that this mechanism can be targeted to attack cancer cells, with potential for improved treatment outcomes. The discovery has the potential to prolong patient benefit from antiangiogenic treatments.
A study found that breast cancer patients who did not adhere to their medication schedule for chronic conditions before diagnosis were twice as likely to skip oral adjuvant hormonal therapy. Non-adherence rates were higher among women with certain age groups, medical specialties, and co-payments.
Researchers at University College London have successfully targeted an autoimmune condition in mice using cancer drugs being tripped in human patients. The study found that by blocking a specific genetic key, the immune system's aggressive response could be prevented, reducing inflammation and damage.
Researchers found that a plant-virus-based carrier successfully delivers the drug candidate phenanthriplatin, outperforming cisplatin in mouse models of triple-negative breast cancer. The nanoparticles target tumors, accumulating inside lysosomal compartments and releasing the drug to block transcription, leading to greater cell death.
Researchers developed a device that can absorb up to 90% of chemotherapy drugs in 25-30 minutes, reducing their circulation and potential harm. The system targets tumors with a concentrated dose while capturing the majority of drugs like a sponge, potentially improving treatment outcomes.
A large, randomized international trial has shown that immunotherapy, specifically nivolumab, significantly improves overall survival and quality of life in patients with rapidly progressing head and neck carcinoma. The treatment also demonstrated a lower rate of serious adverse events compared to standard chemotherapy.
A new method aims to spot scientifically viable cancer research projects and eliminate unsound initiatives. By pooling resources and sponsoring multiple ventures, investors can share high development costs and reduce risks.
Researchers developed a new compound to target mutated p53 genes, found in over 50% of cancers, which are responsible for uncontrolled cell growth. The treatment has shown promising results in patients with modest toxicity, and trials will now expand to 400 patients across Europe and the USA.
Researchers developed an innovative imaging model to track drug resistance and identify a new therapeutic target for pancreatic cancer. The study revealed that the Musashi gene plays a critical role in promoting aggressive disease and found effective antisense inhibitors against Msi, halting tumor growth and improving survival.
A clinical trial shows atezolizumab, a checkpoint inhibitor, is effective in treating advanced bladder cancer, shrinking tumors and stopping new growth. The drug was well-tolerated, with mild side effects, and half of patients responded within 15 weeks.
A clinical trial found that patients with tumors overexpressing DLL3 responded better to the experimental drug rovalpituzumab tesirine (Rova-T), achieving stabilization of disease and significant tumor reductions. The results suggest Rova-T may be a promising treatment option for advanced small cell lung cancer.
A phase II clinical trial found that pembrolizumab reduces tumor size in four types of soft tissue sarcomas and three types of bone sarcomas. Undifferentiated pleomorphic and osteosarcoma subtypes showed particularly promising results, with 44% and 30-40% reductions in tumor size, respectively.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in the treatment of endometrial and ovarian cancers. A Phase II trial combining everolimus, letrozole, and metformin shows a 67 percent clinical benefit rate for patients with recurrent endometrioid endometrial cancer. Additionally, hormonal maintenance therap...
A Phase I/II clinical trial found that nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of PD-L1 marker presence. The treatment was well-tolerated and showed a median survival of at least one year for 45.6% of patients.
A study found that while overall colorectal cancer rates are decreasing, the incidence of late-stage cancer in young patients is increasing. The study, which analyzed data from Colorado patients, reveals a significant rise in late-stage CRC diagnoses among those under 50.
A phase II clinical study found a 32% clinical benefit in pancreatic cancer patients with BRCA mutation, including one complete response and two partial responses. The drug's acceptable safety profile suggests it may be an option earlier in the treatment course for some patients.
A recent study found that over one-in-four cancer patients struggle to afford medical care, leading to missed appointments and prescription delays. The researchers highlight the need for support programs to help patients navigate financial difficulties.
Researchers found that patients who used metformin before diagnosis had a higher risk of death, while those who started using it after diagnosis were more likely to survive. Metformin also showed promise as a treatment for endometrial hyperplasia, with 56% of patients responding to treatment.
Researchers at Kyoto University have identified a genetic mechanism that could predict effectiveness of cure for certain cancers. Genetic alterations affecting the PD-L1 protein allow cancer cells to escape immune detection, but these abnormalities were found in many common cancer types.
Scientists at The Institute of Cancer Research have developed a new method to assess cancer treatment efficacy by measuring blood metabolite levels. This approach has the potential to speed up the development of targeted drugs and tailor treatment for patients, offering a quick and simple way to monitor cancer therapy.
A new treatment shows promise against a rare and deadly eye cancer by blocking the protein ARF6, which distributes cancer-promoting signals. The study found that inhibiting ARF6 inhibited eye tumors in mice, suggesting a potential strategy for treating other cancers as well.
Researchers have created a new mouse model to evaluate CD40-antibody drugs with improved accuracy, advancing those more likely to be effective in patients. The study found that engagement of the human Fc receptor FcRIIB is essential for therapeutic activity, while FcRIIA compromises it.
Researchers at the University of Delaware have developed a new process that triggers targeted reactions using red or near-infrared light or a tiny dose of an enzyme. This breakthrough has significant implications for medicine and engineering, particularly in drug delivery and tissue engineering.
A new study from Mount Sinai researchers reports a high success rate for a personalized medicine program that uses an integrated genomic approach to guide cancer treatment. The program led to therapeutic recommendations for 91% of patients, outperforming targeted cancer panels in clinical use.
Scientists from Gladstone Institutes identified salicylic acid's cancer-fighting properties by inhibiting epigenetic regulators p300 and CBP. Salicylic acid suppresses inflammation and cell growth, offering new clinical possibilities for drugs like aspirin and diflunisal.
Researchers have synthesized a new drug, HA15, that reduces melanoma cell viability without being toxic to normal cells. This breakthrough discovery has the potential to improve treatment outcomes for patients with skin cancer.
A new blood test has identified a subset of patients with stomach cancer who are most likely to respond to treatment. The test measures the number of copies of the FGFR2 gene in cancer DNA circulating in the bloodstream, revealing that tumours with many copies of this gene were particularly susceptible to an experimental drug.
Scientists have made a breakthrough in visualizing proteins involved in cancer cell metabolism using cryo-EM. They were able to capture images of glutamate dehydrogenase at an atomic level, revealing new insights into potential drug targets. This discovery has the potential to revolutionize and accelerate the drug discovery process.
SWOG investigators report on clinical trials for lung, prostate, breast, and other cancers, including Lung-MAP precision medicine trial. Trial results also highlight the reliability of CT scan tumor measurements for evaluating new drug effectiveness.
A Mayo Clinic study analyzed 55 cancer drugs approved using surrogate endpoints, finding that many lacked formal empirical verification. The FDA's reliance on these surrogates may compromise patient outcomes and drug safety.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have identified a new regulator of immune responses, PSGL-1, which acts as a negative regulator of T cell function. The study found that PSGL-1 is required to increase levels of immune checkpoints, allowing T cells to remain active longer than normal.
Researchers found that celecoxib, a widely prescribed pain and anti-inflammatory drug, slows the growth rate of neurofibromatosis type II (NF2) tumors in animal models. The study suggests that COX-2 inhibitors may have an impact on tumor formation and inflammatory responses.
Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment. The U.S. Food and Drug Administration has granted PAC-1 orphan drug status for the treatment of glioblastoma multiforme, a deadly brain cancer with limited therapeutic options.
Researchers at Sylvester Comprehensive Cancer Center identified a novel treatment option for triple-negative breast cancer (TNBC) by targeting vitamin D and androgen receptors. This approach showed promising results in reducing the sustainability of cancer cells, offering new hope for patients with this aggressive form of breast cancer.
A new research paper by GMU and Inova Health System highlights the importance of proteins in personalized medicine, particularly in cancer treatment. The study suggests that targeting proteins can lead to more effective treatments for patients with metastatic breast cancer.
Researchers have identified a chemical compound eCF506 that effectively blocks breast cancer cell growth, targeting a specific molecule required for tumor progression. The findings suggest eCF506 may be more effective and have fewer side effects than existing drugs, with further studies needed to confirm its potential.
A new study reveals that suppressing a key protein, Chitinase 3-like-1 (CHI3L1), restores multiple antitumor responses in the lungs of mice, preventing cancer spread. Researchers tested an intervention that boosted the RIG-like helicase pathway, which counteracts CHI3L1's effects and decreases tumor-inducing responses.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that adolescent girls with high saturated-fat diets and low unsaturated-fat intake had higher breast densities, which may increase their risk for breast cancer later in life. The researchers analyzed data from 177 women and observed a significant association betwee...
A new study using mice and lab-grown human cells shows a triple-drug cocktail can shrink triple-negative breast cancers by killing off cancer cells and halting new tumor growth. The combination treatment, EAD therapy, reduced the size of tumors in mice and decreased tumor growth in spheres grown from patients' metastatic cells.
A new study shows success with a combination therapy of the sugar 2-Deoxy-D-glucose (2-DG) and fenofibrate, which selectively starves slow-growing cancer cells while sparing normal cells. This approach eliminates toxic chemotherapy side effects, paving the way for non-toxic treatments for various cancers.
Researchers designed a novel mTOR inhibitor, Rapalink, to combat drug-resistant tumors. In animal experiments, Rapalink reduced the size of tumors resistant to earlier-generation inhibitors.
A recent study published in JAMA Internal Medicine found that higher levels of leisure-time physical activity were associated with lower risks for 13 types of cancers. The analysis included 1.4 million participants and 186,932 cancers identified during a median of 11 years of follow-up.
The 2016 Asia Pacific Lung Cancer Conference presented the latest advances in lung cancer research, including immunotherapy and multidisciplinary practices. Tobacco use was also a major concern, with experts emphasizing the need for stricter control measures to reduce deaths from lung cancer in Southeast Asia.
Researchers are exploring genetically modified pigs as a valuable alternative to rodent models for cancer research, leveraging precision-genetics and genetic similarities between swine and humans. This approach could lead to more accurate modeling of the disease and identification of effective treatments.
A new blood marker, FCGR2A, identifies patients with metastatic colorectal cancer who will benefit from the drug cetuximab. The discovery helps personalize cancer medicine for those with colorectal disease, improving treatment outcomes.
Researchers have found that a specific blood marker is common among patients with a subset of metastatic colorectal cancer, increasing their chances of responding to the drug. This breakthrough builds on an international clinical trial and could lead to more effective treatment options for patients running out of time.
A genetic variation in the VAC14 gene is highly associated with docetaxel-induced peripheral neuropathy in prostate cancer patients. This finding could lead to more personalized treatment approaches and reduced side effects.
A single defect in a histone gene has been linked to pediatric cancers, with researchers finding that the mutation can form a tumor on its own. The discovery could lead to new treatment options for metastatic breast cancer and provide insights into human development.
Dr. Nita Maihle is leading a national DOD initiative to support early career ovarian cancer investigators. The program aims to foster team science and improve understanding of the disease. With a focus on secretory cells that line the fallopian tubes, researchers hope to develop targeted therapies for this deadly form of cancer.
A new study links MS drug mitoxantrone to an increased risk of colorectal cancer, with patients treated with the medication being three times more likely to develop the disease. However, the overall rate of cancer was low enough that the researchers suggest continuing its use for severely affected patients.
Researchers have identified genetic variations in the PKC alpha enzyme that boost its activity and contribute to the development of Alzheimer's disease. These variants were found in five families with late-onset Alzheimer's disease and are associated with increased PKC alpha activity.
Scientists at Scripps Research Institute designed a drug candidate that targets cancer-causing RNA, eliminating side effects and reducing tumor growth. The study demonstrates a clear breakthrough in precision medicine, using computational approaches to develop designer compounds.
Researchers identified three subtypes of ACC with distinct clinical outcomes and molecular alterations. The study also found novel ACC driver genes and suggests that inhibiting whole genome doubling could slow tumor growth. These findings may inform therapeutic decisions and lead to significant advances in patient outcomes.
Researchers found more than half of the genes studied showed sex-biased signatures in certain cancer types, revealing two sex-effect groups associated with distinct incidence and mortality profiles. These findings lay a critical foundation for precision cancer medicine that is sex-specific.
Researchers at Sylvester Comprehensive Cancer Center have developed an animal model of multiple myeloma, allowing them to better understand its mechanisms and test potential treatments. The study has the potential to improve outcomes for patients with this incurable disease.
Researchers at UC San Diego School of Medicine showed ozanimod moderately effective in treating ulcerative colitis. Ozanimod reduced rectal bleeding and healed intestinal mucosal lining.
Researchers identified 43 genes with autism susceptibility also linked to cancer, potentially leading to repurposed treatments. Common biological mechanisms may enable personalized medicines for neurodevelopmental disorders.